Frederick M. Hudson - 07 Oct 2025 Form 4 Insider Report for scPharmaceuticals Inc. (SCPH)

Reporting relationship: Director
Issuer ticker: SCPH
Reported as of: 07 Oct 2025
Net transaction value: $0
SEC form: 4
Accepted by SEC: 07 Oct 2025, 16:30:11 UTC
Prior SEC filing: 18 Aug 2025
Next SEC filing: 12 Jan 2026
Source filing: View source filing
Reporting owner signature: /s/ John H. Tucker, attorney-in-fact

Key filing fact

Frederick M. Hudson filed Form 4 for scPharmaceuticals Inc. (SCPH) on 07 Oct 2025.

Key facts

This page summarizes Frederick M. Hudson's Form 4 filing for scPharmaceuticals Inc. (SCPH).
4 reported transactions and 4 derivative rows are listed below.
Accepted by SEC: 07 Oct 2025, 16:30.

Change

Previous filing in this sequence was filed on 18 Aug 2025.
Current net transaction value: $0.

Research use

This tells you what this filing adds before you inspect full transaction and derivative tables.
You can trace every row back to the original SEC filing document.

Evidence

Filed on Form 4

Ownership activity is grounded in SEC Form 4 disclosures.

View source filing

Reporting Owners (1)

CIK 0001438462 Primary reporting owner

Hudson Frederick M.

Relationship: Director
Address: C/O SCPHARMACEUTICALS INC, 25 BURLINGTON MALL ROAD, SUITE 203, BURLINGTON
Signature: /s/ John H. Tucker, attorney-in-fact
Signature date: 07 Oct 2025

Reported derivative securities

Options, warrants, convertible securities, or similar derivative positions disclosed in the filing.

SCPH transaction Derivative

Stock Option (Right to Buy)

Disposed to Issuer

Transaction value: $0
Shares: -30,000
Change %: -100%
Price: $0.000000
Shares after: 0
Date: 07 Oct 2025
Ownership: Direct
Underlying class: Common Stock
Underlying amount: 30,000
Exercise price: $3.85
Footnotes: F1, F2

SCPH transaction Derivative

Stock Option (Right to Buy)

Disposed to Issuer

Transaction value: $0
Shares: -19,750
Change %: -100%
Price: $0.000000
Shares after: 0
Date: 07 Oct 2025
Ownership: Direct
Underlying class: Common Stock
Underlying amount: 19,750
Exercise price: $4.11
Footnotes: F1, F2

SCPH transaction Derivative

Stock Option (Right to Buy)

Disposed to Issuer

Transaction value: $0
Shares: -16,300
Change %: -100%
Price: $0.000000
Shares after: 0
Date: 07 Oct 2025
Ownership: Direct
Underlying class: Common Stock
Underlying amount: 16,300
Exercise price: $4.53
Footnotes: F1, F2

SCPH transaction Derivative

Stock Option (Right to Buy)

Disposed to Issuer

Transaction value: $0
Shares: -6,124
Change %: -100%
Price: $0.000000
Shares after: 0
Date: 07 Oct 2025
Ownership: Direct
Underlying class: Common Stock
Underlying amount: 6,124
Exercise price: $3.37
Footnotes: F1, F2

^* marks a reported price that did not pass the local price check.

Additional SEC filing notes

Filing notes and footnotes

Section 16 status

Frederick M. Hudson is no longer subject to Section 16 filing requirements. Form 4 or Form 5 obligations may still apply in specific circumstances.

Explanation of responses 2 footnotes

Footnote F1

In connection with the terms of an Agreement and Plan of Merger, dated as of August 24, 2025 (the "Merger Agreement"), by and among the Issuer, MannKind Corporation ("Parent") and Seacoast Merger Sub, Inc., a direct wholly owned subsidiary of Parent ("Purchaser"), Purchaser completed a tender offer for shares of the Issuer's common stock ("Common Stock") on October 7, 2025. Pursuant to the terms of the Merger Agreement, immediately prior to the Effective Time, each option to purchase shares of Common Stock (a "Company Option") that was outstanding and unexercised as of immediately prior to the Effective Time and that had an exercise price per share that was less than $5.35, whether or not then vested or exercisable,

Footnote F2

(Continued from footnote 1) was cancelled and converted into the right to receive (i) an amount in cash, without interest and subject to any applicable withholding taxes, equal to (A) the total number of shares subject to such Company Option immediately prior to such cancellation multiplied by (B) the excess, if any, of (x) $5.35 over (y) the exercise price payable per share underlying such Company Option and (ii) one CVR in respect of each share subject to such Company Option.